title: [Active surveillance of localized prostate cancer. Significance of prostate core needle biopsies].
abstract: Today, more than 80% of men diagnosed with prostate cancer (PCA) by PSA screening do not die from the sequelae of their disease. About 70% present with early, organ-confined cancer and almost half of them are small (<5 cm(3)) without evidence of progression over years (insignificant PCA). It is assumed that screening brings the diagnosis of PCA forward by about 9 years and that in almost one third of these cases immediate radical prostatectomy or radiotherapy would result in overtreatment. Thus, the treatment strategy of "active surveillance" with selective but delayed intervention for patients with organ-confined PCA could be an attractive alternative to the known curative therapy options. However, a prerequisite of such a therapeutic approach would be a precise identification of patients at high risk for cancer progression. Careful work-up of prostate core needle biopsies including improved pre-embedding preparation and detailed interpretation are of the utmost importance. A Gleason score < or =6 and tumor in only one or two cores are considered predictive of organ-confined cancer. Pathologists should concentrate on correct Gleason scoring in core needle biopsies and identification of lesions that exclude a patient from active surveillance.
authors.affiliation: Institut für Pathologie Nordhessen, Wilhelmshöher Allee 287, 34131, Kassel. rueschoff@patho-nordhessen.de
authors.forename: J
authors.initials: J
authors.lastname: Rüschoff
authors.forename: P
authors.initials: P
authors.lastname: Middel
authors.forename: P
authors.initials: P
authors.lastname: Albers
mesh_terms: D015415:Biomarkers; D001706:Biopsy; D001707:Biopsy, Needle / Q000379:methods; D018450:Disease Progression; D006801:Humans; D008297:Male; D008403:Mass Screening; D011237:Predictive Value of Tests; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000473:pathology*
chemical_list: D015415:Biomarkers; D017430:Prostate-Specific Antigen